A Cohort Study in Newly Diagnosed MZL

Recruiting now

Conditions studied: Marginal Zone Lymphoma

In brief

Describe the clinical features, diagnosis and treatment status, disease course and primary outcomes of different subtypes of marginal zone B-cell lymphoma (MZL), observe the therapeutic efficacy and safety of different treatment modalities.

Key facts

Study ID

NCT06449885

Run by

Fudan University

People needed

2500

Starts

2024-05-30

Expected to finish

2034-06-30

Last updated by the study team

2025-11-19

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age≥ 18 years old; Male or female.
• Newly diagnosed marginal zone lymphoma by histopathology within the past 6 months (180 days) and no anti-tumor therapy (including chemotherapy, radiotherapy, and biological therapy or immunotherapy for the treatment of tumors).
• Willing to provide biological samples required for the study, including blood samples and tumor tissue.
• Voluntarily join this study and sign the informed consent form.
• Willing to accept long-term follow-up.

You may not qualify if…

• Patients with HIV infection.
• Those who cannot come to the hospital regularly for follow-up.
• Those with comorbidities and speech impairment.

Where it is running

• Fudan University Shanghai Cancer Center — Shanghai, Shanghai Municipality, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.